Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met

Anaplastic lymphoma kinase (ALK) is a validated molecular target for patients harboring ALK rearrangement, which triggers the development of ALK inhibitors. However, the activation of mesenchymal-epithelial transition factor (c-Met) has emerged as a common cause of acquired resistance induced by sel...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Am J Cancer Res
Prif Awduron: Wang, Lei, Gao, Mingzhao, Tong, Mengya, Xie, Chengying, He, Ye, Fu, Li, Li, Yun, Fu, Haoyu, Lou, Liguang
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: e-Century Publishing Corporation 2018
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6129499/
https://ncbi.nlm.nih.gov/pubmed/30210922
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg